PCNA and neoplasm: To corroborate these findings of specific MPE, but not tumor growth suppression by NF-κB-tailored bortezomib treatment, we next assessed the proliferation and apoptosis of tumor cells in vivo using PCNA and TUNEL labeling, respectively (Figure 4).